Adjuvant Treatment for Early-Stage Ovarian Cancer
Author Information
Author(s): Bamias Aristotle, Papadimitriou Christos, Efstathiou Eleni, Rodolakis Alexandros, Vlahos Georgios, Voulgaris Zannis, Bozas Georgios, Fountzilas Georgios, Aravantinos Gerassimos, Razis Evagelia, Gika Dimitra, Dimopoulos Meletios A
Primary Institution: Hellenic Cooperative Oncology Group
Hypothesis
Can paclitaxel and carboplatin improve outcomes in early-stage ovarian cancer patients?
Conclusion
Paclitaxel/Carboplatin chemotherapy is a safe and effective adjuvant treatment in early-stage ovarian carcinoma.
Supporting Evidence
- The 5-year overall survival rate was 87%.
- The 5-year relapse-free survival rate was 79%.
- Grade 3 or 4 neutropenia occurred in 29.9% of patients.
Takeaway
This study shows that a specific chemotherapy can help women with early-stage ovarian cancer feel better and live longer.
Methodology
Patients with early-stage ovarian cancer received 4 cycles of paclitaxel and carboplatin after surgery.
Potential Biases
Potential bias due to the retrospective nature and non-randomized design.
Limitations
The study is retrospective and may have selection bias.
Participant Demographics
Patients were predominantly women with early-stage epithelial ovarian cancer.
Statistical Information
P-Value
0.03
Confidence Interval
95% CI: 78–96 for OS, 95% CI: 69–89 for RFS
Statistical Significance
p = 0.03
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website